Effect of Bioactive Component and Antiproliferative Potential of Ganoderma Spp . on Cultured Human Breast Adenocarcinoma (Mcf‐7) Cell Line

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Antiproliferative activity of selected medicinal plants of Jordan against a breast adenocarcinoma cell line (MCF7)

76 ethanolic extracts of medicinal herbs from the Jordanian flora, belonging to 67 species and 34 families, were evaluated for their antiproliferative activity on a breast cancer cell line (MCF7). The cells were cultured in RPMI 1640 medium and incubated with the extracts for 72 hours. Sulphorhodamine B (SRB) assay was used to test cytotoxicity. From the tested crude extracts, Inula graveolens,...

متن کامل

Effect of citric acid on Bioavailability and apoptosis induction in human colorectal Adenocarcinoma cell line (HT29)

Background and Aim: Colorectal adenocarcinoma is one of the common causes of death due to weak response to common therapies. In this study, the effect of citric acid on bioavailability and apoptosis of the human colorectal adenocarcinoma cell line (HT29) was examined. Citric acid is a naturally organic acid that commonly found in citrus and is considered as a physiological inhibitor of enzymes ...

متن کامل

Antiproliferative Effect of Aspirin on Colorectal Cancer Cell Line

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Aspirin may have anticancer properties, and can be effective as a novel strategy for the treatment of colorectal cancer (CRC). The aim of this study was to assess the cytotoxic effects of Aspirin drug in CRC cell lines compared with Oxaliplatin drug in vitro. Methods: Cell viability was assessed after treatment of SW742 and SW48...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: The FASEB Journal

سال: 2019

ISSN: 0892-6638,1530-6860

DOI: 10.1096/fasebj.2019.33.1_supplement.782.1